Sekar Kathiresan Verve Therapeutics, Inc. (VERV) insider trading activity

Sekar Kathiresan is Chief Executive Officer of Verve Therapeutics, Inc.. Currently has a direct ownership of 346,686 shares of VERV, which is worth approximately $3.84 Million. The most recent transaction as insider was on Apr 02, 2025, when has been sold 9,822 shares (Common Stock) at a price of $4.15 per share, resulting in proceeds of $40,761. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 347K

0% 3M change

1.27% 12M change

Total Value Held $3.84 Million

Sekar Kathiresan Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Apr 02 2025	SELL Open market or private sale	$40,761 $4.15 p/Share	9,822 Reduced 2.76%	346,686 Common Stock
Apr 01 2025	BUY Exercise of conversion of derivative security	-	33,000 Added 8.47%	356,508 Common Stock
Dec 04 2024	SELL Bona fide gift	-	30,000 Reduced 8.49%	323,508 Common Stock
Jun 28 2024	BUY Exercise of conversion of derivative security	$86,100 $2.87 p/Share	30,000 Added 7.87%	351,128 Common Stock
Oct 03 2022	SELL Open market or private sale	$1,702,000 $34.04 p/Share	50,000 Reduced 13.59%	317,839 Common Stock
Oct 03 2022	BUY Exercise of conversion of derivative security	$69,500 $1.39 p/Share	50,000 Added 11.97%	367,839 Common Stock
Aug 10 2022	SELL Open market or private sale	$1,495,000 $29.9 p/Share	50,000 Reduced 13.59%	317,839 Common Stock
Aug 10 2022	BUY Exercise of conversion of derivative security	$69,500 $1.39 p/Share	50,000 Added 11.97%	367,839 Common Stock
Jul 19 2022	SELL Open market or private sale	$1,495,000 $29.9 p/Share	50,000 Reduced 13.59%	317,839 Common Stock
Jul 19 2022	BUY Exercise of conversion of derivative security	$69,500 $1.39 p/Share	50,000 Added 11.97%	367,839 Common Stock
Jul 07 2022	SELL Bona fide gift	-	160,000 Reduced 33.48%	317,839 Common Stock
Mar 18 2022	BUY Exercise of conversion of derivative security	$199,964 $2.87 p/Share	69,674 Added 12.73%	477,525 Common Stock
Jan 04 2022	SELL Open market or private sale	$74,613 $39.9 p/Share	1,870 Reduced 0.46%	406,536 Common Stock
Jan 04 2022	BUY Exercise of conversion of derivative security	$2,599 $1.39 p/Share	1,870 Added 0.46%	408,406 Common Stock
Dec 28 2021	SELL Open market or private sale	$267,051 $39.9 p/Share	6,693 Reduced 1.62%	406,536 Common Stock
Dec 28 2021	BUY Exercise of conversion of derivative security	$9,303 $1.39 p/Share	6,693 Added 1.59%	413,229 Common Stock
Dec 27 2021	SELL Open market or private sale	$1,728,720 $41.16 p/Share	42,000 Reduced 9.36%	406,536 Common Stock
Dec 27 2021	BUY Exercise of conversion of derivative security	$58,380 $1.39 p/Share	42,000 Added 8.56%	448,536 Common Stock
Dec 23 2021	SELL Open market or private sale	$2,274,300 $39.9 p/Share	57,000 Reduced 12.3%	406,536 Common Stock
Dec 23 2021	BUY Exercise of conversion of derivative security	$79,230 $1.39 p/Share	57,000 Added 10.95%	463,536 Common Stock
Dec 22 2021	SELL Open market or private sale	$2,201,910 $38.63 p/Share	57,000 Reduced 12.3%	406,536 Common Stock
Dec 22 2021	BUY Exercise of conversion of derivative security	$79,230 $1.39 p/Share	57,000 Added 10.95%	463,536 Common Stock
Jun 21 2021	BUY Open market or private purchase	$47,500 $19.0 p/Share	2,500 Added 0.61%	406,536 Common Stock

Also insider at

RLAY

Relay Therapeutics, Inc. Healthcare